Sentiment Change Report: Celgene Corp (NASDAQ:CELG) at 0.93

Celgene Corporation (NASDAQ:CELG) Corporate Logo

Celgene Corp’s Sentiment

In 2018 Q3 Celgene Corp (NASDAQ:CELG) big money sentiment increased to 0.93, according to Securities and Exchange Commission filings. That’s up 0.22, from 2018Q2’s 0.71. 445 institutional investors started new or increased stock positions, while 476 sold and decreased stock positions in Celgene Corp so the sentiment is better. Funds own 468.90 million shares, down from 476.86 million shares in 2018Q2. Funds holding Celgene Corp in top 10 changed to 21 from 21 for the same number . In total 58 funds closed positions, 418 reduced and 332 increased. Also 113 funds bought new Celgene Corp stakes.

Biggest Celgene Corp Investors

As of 2018 Q3 Oaktop Capital Management Ii L.P. has 41.38% invested in Celgene Corp. As of 2018 Q3, 670,181 shares of Celgene Corp are owned by Birchview Capital Lp. Moreover, Selkirk Management Llc reported 270,000 shares in Celgene Corp equivalent to 12.31% of its fund portfolio. Taylor Asset Management Inc revealed 294,300 shares position in Celgene Corp. The Switzerland-based fund Bb Biotech Ag looks positive on Celgene Corp, having 2.98 million shares.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide.The firm is valued at $60.89 billion. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes , and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.22.64 is the P/E ratio. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products.

CELG is touching $86.95 during the last trading session, after decreased 0.64%.Celgene Corporation has volume of 3,864 shares. Since January 11, 2018 CELG has declined 33.15% and is downtrending. CELG underperformed by 33.15% the S&P 500.

Celgene Corporation (NASDAQ:CELG)’s quarterly earnings will be reported on January, 24., as reported by Faxor. Analysts expect change of 11.23 % or $0.21 from previous year’s $1.87 earnings per share compared to current’s $2.08 earnings per share. The profit will be $1.46B for CELG if $2.08 earnings per share becomes true. Last quarter $2.03 earnings per share was reported. Analysts sees 2.46 % EPS growth this quarter.

Cap Mngmt Associate reported 2,700 shs. North Star Inv Mngmt Corp holds 0.37% or 36,820 shs. Moreover, Westend Lc has 0% invested in Celgene Corporation (NASDAQ:CELG). Cobblestone Advisors Ltd Liability, a New York-based fund reported 14,068 shs. Putnam Ltd Limited Liability Company stated it has 0.03% in Celgene Corporation (NASDAQ:CELG). Tealwood Asset Management Inc holds 0.5% or 14,930 shs in its capital. Ccm Investment Advisers Ltd Liability holds 5,875 shs or 0.1% of its capital. Amalgamated Bankshares reported 106,392 shs. State Of New Jersey Common Pension Fund D holds 830,000 shs or 0.27% of its capital. Steinberg Glob Asset Management reported 0.14% in Celgene Corporation (NASDAQ:CELG). United Services Automobile Association stated it has 916,299 shs. Psagot House Limited owns 160,985 shs. Chicago Equity Ltd Com owns 50,495 shs for 0.13% of their capital. Whitnell holds 0.11% or 3,200 shs in its capital. Kingfisher Cap Limited Liability Com reported 9,387 shs.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

In total 7 analysts cover Celgene (NASDAQ:CELG). “Buy” rating has 2, “Sell” are 0, while 5 are “Hold”. 29% are bullish. With $100 highest and $77 lowest price target Celgene has $88.17 average price target or 1.40% above the current ($86.95) price. 9 are the (NASDAQ:CELG)’s analyst reports since July 13, 2018 according to StockzIntelligence Inc. In Friday, January 4 report Robert W. Baird upgraded the stock to “Outperform” rating. On Friday, December 21 the stock of Celgene Corporation (NASDAQ:CELG) earned “Neutral” rating by BTIG Research. In Friday, January 4 report Wells Fargo maintained the stock with “Market Perform” rating. On Wednesday, December 19 the rating was maintained by Morgan Stanley with “Equal-Weight”. On Monday, December 17 the rating was maintained by Citigroup with “Neutral”. On Friday, January 4 the stock of Celgene Corporation (NASDAQ:CELG) has “Neutral” rating given by Goldman Sachs. The stock rating was maintained by Morgan Stanley with “Equal-Weight” on Friday, July 27. On Friday, July 13 the firm earned “Equal-Weight” rating by Morgan Stanley.

For more Celgene Corporation (NASDAQ:CELG) news released recently go to: Seekingalpha.com, Nasdaq.com, Seekingalpha.com, Nasdaq.com or Fool.com. The titles are as follows: “Buying Celgene – Celgene Corporation (NASDAQ:CELG) – Seeking Alpha” released on January 11, 2019, “Celgene (CELG) Dips More Than Broader Markets: What You Should Know – Nasdaq” on December 28, 2018, “Bristol-Myers Squibb may be takeover target after Celgene bid – Credit Suisse – Seeking Alpha” with a publish date: January 08, 2019, “3 of the Cheapest Drug Stocks You Can Buy in 2019 – Nasdaq” and the last “Here’s Why CRISPR Therapeutics Tanked 25.5% in December – Motley Fool” with publication date: January 07, 2019.

Celgene Corporation (NASDAQ:CELG) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.